Thermosensitive In Situ Ophthalmic Gel for Effective Local Delivery and Antifungal Activity of Ketoconazole Nanoparticles.

Chutima Chaiwut, Sarin Tadtong, Puriputt Akachaipaibul, Jutamas Jiaranaikulwanitch, Sudarshan Singh, Siriporn Okonogi, Dwi Marlina Syukri, Chuda Chittasupho
Author Information
  1. Chutima Chaiwut: Master's Degree Program in Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
  2. Sarin Tadtong: Faculty of Pharmacy, Srinakharinwirot University, Nakhonnayok 26120, Thailand.
  3. Puriputt Akachaipaibul: Faculty of Pharmacy, Srinakharinwirot University, Nakhonnayok 26120, Thailand.
  4. Jutamas Jiaranaikulwanitch: Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand. ORCID
  5. Sudarshan Singh: Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand. ORCID
  6. Siriporn Okonogi: Center of Excellence in Pharmaceutical Nanotechnology, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand. ORCID
  7. Dwi Marlina Syukri: Department of Microbiology, Faculty of Medicine, Malahayati University, Lampung 35153, Indonesia.
  8. Chuda Chittasupho: Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand. ORCID

Abstract

Fungal keratitis is a severe ocular infection caused by pathogenic fungi, leading to potential vision loss if untreated. Current antifungal treatments face limitations such as low solubility, poor corneal penetration, and limited therapeutic options. This study aimed to develop a thermosensitive in situ gel incorporating ketoconazole nanoparticles (NPs) to enhance drug solubility, stability, and antifungal activity. Ketoconazole NPs were prepared using the solvent displacement method, achieving a particle size of 198.25 ± 27.51 nm, encapsulation efficiency of 94.08 ± 0.51%, polydispersity index of 0.42 ± 0.08, and a positive zeta potential value of +10.08 ± 0.19 mV. The NPs exhibited sustained zero-order release kinetics. The optimized NPs were incorporated into a poloxamer-based in situ gel, demonstrating a gelation temperature of 34.67 ± 0.58 °C and the shortest gelation time. The formulation provided a 5-fold increase in solubility and a 10-fold improvement in drug release compared to pure ketoconazole. Stability studies confirmed the gel retained its physicochemical and rheological properties for three months under various storage conditions. The in situ gel showed sustained release, effective antifungal activity against , and good tolerability, suggesting it as a promising alternative for treating fungal keratitis with improved bioavailability and patient compliance.

Keywords

References

  1. Carbohydr Polym. 2020 Jul 15;240:116268 [PMID: 32475558]
  2. J Ocul Pharmacol Ther. 2008 Oct;24(5):501-6 [PMID: 18803444]
  3. Small. 2024 Jan;20(3):e2304713 [PMID: 37675812]
  4. Pharmaceutics. 2023 Mar 04;15(3): [PMID: 36986701]
  5. Pharmaceutics. 2021 Jan 24;13(2): [PMID: 33498849]
  6. Adv Colloid Interface Sci. 2023 Apr;314:102871 [PMID: 36958181]
  7. Pharmaceuticals (Basel). 2021 Jul 15;14(7): [PMID: 34358106]
  8. Pharm Dev Technol. 2010 Jul-Aug;15(4):386-93 [PMID: 19772380]
  9. Int J Pharm. 2022 Feb 5;613:121409 [PMID: 34952148]
  10. Int J Pharm. 2000 Mar 30;198(1):1-6 [PMID: 10722946]
  11. Sci Pharm. 2011;79(4):817-36 [PMID: 22145107]
  12. Polymers (Basel). 2022 Mar 11;14(6): [PMID: 35335465]
  13. Gels. 2023 Jan 18;9(2): [PMID: 36826248]
  14. Gels. 2024 Apr 15;10(4): [PMID: 38667685]
  15. Pharmaceutics. 2024 Jun 02;16(6): [PMID: 38931873]
  16. Eur J Pharm Biopharm. 2017 May;114:119-134 [PMID: 28126392]
  17. Int J Mol Sci. 2022 Mar 02;23(5): [PMID: 35269898]
  18. Int J Pharm. 2012 Jul 1;430(1-2):114-9 [PMID: 22503953]
  19. J Ophthalmol. 2014;2014:173298 [PMID: 24872888]
  20. Pharmaceutics. 2019 Dec 10;11(12): [PMID: 31835628]
  21. Nanomaterials (Basel). 2024 Aug 14;14(16): [PMID: 39195385]
  22. Polymers (Basel). 2022 Apr 29;14(9): [PMID: 35567002]
  23. Biomedicines. 2022 Aug 23;10(9): [PMID: 36140156]
  24. PLoS One. 2013 Jul 01;8(7):e67495 [PMID: 23840873]
  25. Artif Cells Nanomed Biotechnol. 2018 Sep;46(6):1282-1287 [PMID: 28826241]
  26. Pharmaceuticals (Basel). 2023 Jun 09;16(6): [PMID: 37375809]
  27. J Cosmet Dermatol. 2006 Sep;5(3):218-26 [PMID: 17177743]
  28. Lancet Infect Dis. 2021 Mar;21(3):e49-e57 [PMID: 33645500]
  29. Polymers (Basel). 2022 Sep 01;14(17): [PMID: 36080699]
  30. Food Chem. 2022 Jun 15;379:132075 [PMID: 35066355]
  31. Vestn Oftalmol. 1990 Jan-Feb;106(1):44-6 [PMID: 2378037]
  32. Int J Pharm. 2023 Nov 25;647:123535 [PMID: 37865132]
  33. Toxicol Mech Methods. 2021 Oct;31(8):572-580 [PMID: 34126859]

Word Cloud

Created with Highcharts 10.0.0gel±0antifungalsituNPssolubility08releasekeratitispotentialketoconazoledrugactivityKetoconazolesustainedgelationpreparationFungalsevereocularinfectioncausedpathogenicfungileadingvisionlossuntreatedCurrenttreatmentsfacelimitationslowpoorcornealpenetrationlimitedtherapeuticoptionsstudyaimeddevelopthermosensitiveincorporatingnanoparticlesenhancestabilitypreparedusingsolventdisplacementmethodachievingparticlesize198252751nmencapsulationefficiency9451%polydispersityindex42positivezetavalue+1019mVexhibitedzero-orderkineticsoptimizedincorporatedpoloxamer-baseddemonstratingtemperature346758°Cshortesttimeformulationprovided5-foldincrease10-foldimprovementcomparedpureStabilitystudiesconfirmedretainedphysicochemicalrheologicalpropertiesthreemonthsvariousstorageconditionsshowedeffectivegoodtolerabilitysuggestingpromisingalternativetreatingfungalimprovedbioavailabilitypatientcomplianceThermosensitiveSituOphthalmicGelEffectiveLocalDeliveryAntifungalActivityNanoparticlesdrugsextemporaneousophthalmic

Similar Articles

Cited By